Search

The aim of the study was to determine the relationship between the degree of progression of liver fibrosis and the risk of cardiovascular complications in patients with Type 2 diabetes mellitus (DM) with non-alcoholic fatty liver disease (NAFLD). The study included 110 patients with Type 2 diabetes (62 men and 48 women), the average age of the subjects was 52.07±1.11 years. All patients were divided into 2 groups: the main group included 72 patients with Type 2 diabetes with concomitant NAFLD (38 men and 34 women); the control group included 38 patients with Type 2 diabetes without clinical manifestations of NAFLD (24 men and 14 women). Patients of the main group were divided into 3 subgroups, taking into account the predominant pathological processes in the clinical picture. The division into subgroups was carried out in 2 stages: at the first stage, those with predominant manifestations of liver fibrosis (F2 or more) were selected from the general population of patients with Type 2 diabetes with NAFLD according to the results of liver elastography and the use of Bonacini and Metavir scales. The number of such patients was 29, which accounted for 40.3% of the total number of patients in the main group. The remaining patients were divided into 2 subgroups: 11 patients (15.3%) had non-alcoholic liver steatosis, and 32 patients (44.4%) had signs of non-alcoholic steatohepatitis (NASH). As a result of the study, it was found that the presence of liver fibrosis in patients with Type 2 diabetes with NAFLD is significantly more often associated with cardiovascular complications, such as arterial hypertension, coronary heart disease, myocardial infarction, stroke, diabetic retinopathy and nephropathy. A significant decrease in the ejection fraction (EF) was found in patients with Type 2 diabetes with concomitant NAFLD. At the same time, the number of patients with EF disorders of varying degrees in the main group significantly exceeded that in the comparison group (33.3% and 6.7%, respectively, p<0.001). The average values of left ventricular myocardial mass are significantly lower in patients with NASH and fibrosis formation compared to patients with NAFLD at the stage of fatty hepatosis. There was also a significant decrease in the size of the left and right atria in patients with NASH compared to both patients with steatosis and patients with fibrotic liver changes. Patients with predominant fibrotic changes in the liver are characterized by a relative decrease in myocardial mass, a decrease in final diastolic and systolic volumes and EF, which may indicate the development of diastolic dysfunction in them. It is shown that it is necessary to take into account in clinical practice not only the generally accepted stages of NAFLD, but also the predominant pathological process in the liver in patients with Type 2 diabetes, namely steatosis, manifestations of inflammation and fibrotic disorders. It is proved that fibrotic changes in the liver can develop at all stages of liver tissue damage. [ABSTRACT FROM AUTHOR]

Copyright of Likarska Sprava is the property of J. Likarska Sprava and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Likarska Sprava is the property of J. Likarska Sprava and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: The aim: To analyze and compare the features of changes in the motor activity of rats on the background of pharmacological models of depressive disorders., Patients and Methods: Materials and methods: Depressive-like state was simulated on 40 mature male Wistar rats using: reserpine (15 mg/kg), clonidine (0.1 mg/kg), haloperidol (0.25 mg/kg). The control group was given as a single dose 0.5 ml of a 0.9% sodium chloride solution intraperitoneally. After 3, 12, 24, 48 and 72 hours from the beginning of the experiment, changes in motor activity in the "open field" test were examined by the number of crossed squares, the calculation was carried out within 5 minutes., Results: Results: Reserpine at a dose of 15 mg/kg caused probable motor activity disorders in rats in the "open field" test during all study periods. The most pronounced inhibition of motor activity was observed within 12-48 hours from the beginning of the experiment. 3 hours after clonidine administration, the number of crossed squares decreased by 310% (p<0.001), after 12 hours - by 180% (p<0.001), after 24 hours - by 140% (p<0.001), after 48 hours - by 50% (p<0.005) in comparison with the control group. On 3rd day, the motor activity of rats was almost completely restored. The use of haloperidol after 3 hours most significantly impaired the motor activity of rats in the "open field" test, and its recovery was observed after 24 hours., Conclusion: Conclusions: Reserpine inhibited the motor activity of rats, most pronounced from 12 to 48 hours of the experiment. Clonidine inhibited mainly in the first hours of the study. Haloperidol impaired motor activity at 3rd and 12th hours of observation.

The presented case report concerns a 62-year-old male patient who was admitted to the rheumatology department with a fever, shoulder and hip joint pain, significant limitation of movement in these joints and general weakness. Laboratory test revealed increase of inflammatory parameters, as ESR and C-reactive protein, rheumatoid factor and ACPA antibodies were absent. In the course of diagnostics, infections and cancer were excluded. The patient met the classification criteria for polymyalgia rheumatica. Polymyalgia rheumatica is not a rare disease, but the number of elderly people in the world continues to increase, and we can assume that the prevalence of this disease will increase in the coming years. At suspicion on polymyalgia rheumatica, it is necessary to exclude other rheumatic diseases, infections and malignant neoplasms. The authors also presented which diseases should be considered in the differential diagnosis., Competing Interests: The authors declare no conflict of interest.